(HealthDay News) – Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.
To compare the sensitivity and specificity of the RNA tests with cytology and NMP22 assays (NMP22 BladderChek and NMP22 enzyme-linked immunosorbent assay [ELISA]) using cystoscopy as the reference, Paul O’Sullivan, MD, of Pacific Edge Ltd. in Dunedin, New Zealand, and associates conducted a prospective study of 485 patients presenting with gross hematuria with no history of urothelial cancer.
Of 66 patients with urothelial carcinoma, the researchers found that uRNA detected 62.1% of the cases, compared with cytology (56.1%), NMP22 ELISA (50%), and BladderChek (37.9%). Cxbladder detected 82% of cases, including 100% of tumors stage 1 or greater and 97% of high-grade tumors. The specificity of Cxbladder and uRNA were prespecified at 85%, and the specificity of cytology, NMP22 ELISA, and BladderChek were 94.5, 88.0, and 96.4%, respectively. Cxbladder was able to differentiate between low-grade Ta tumors and other detected urothelial carcinoma with a sensitivity and a specificity of 91 and 90%, respectively.
“uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays,” the authors write. “Stratification with Cxbladder provides a potential method to prioritize patients for the management of waiting lists.”
Several authors disclosed financial ties (including employment) to Pacific Edge Ltd., which manufactures Cxbladder.